NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00423475,Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer,https://clinicaltrials.gov/study/NCT00423475,,COMPLETED,"RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin, may stop the adrenal glands from making androgens. Giving radiation therapy with or without goserelin after surgery may kill any tumor cells that remain after surgery. It is not yet known whether radiation therapy is more effective with or without goserelin in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy and goserelin to see how well they work compared with radiation therapy alone in treating patients who have undergone surgery for recurrent or refractory prostate cancer.",NO,Prostate Cancer,DRUG: goserelin acetate|PROCEDURE: adjuvant therapy|RADIATION: radiation therapy,"Progression-free (biological and/or clinical) survival, 3.5 years","Overall survival, not yet evaluable|Metastases-free survival, not yet evaluable|Immediate and delayed toxicities, not yet evaluable|Delay in reaching the prostate-specific antigen nadir, not yet evaluable|Quality of life at 1 and 5 years after radiotherapy, not yet evaluable|Functional dependence at 1 and 5 years after radiotherapy in patients age 75 years and over, not yet evaluable",,UNICANCER,AstraZeneca,MALE,"ADULT, OLDER_ADULT",PHASE3,743,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GETUG-AFU 16 - UC-0160/0504|EUDRACT-2005-005165-11|CDR0000523446,2006-10,2015-03,,2007-01-18,,2018-05-17,"Centre Paul Papin, Angers, 49036, France|Institut Sainte Catherine, Avignon, 84082, France|Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, 25030, France|Institut Bergonie, Bordeaux, 33076, France|Centre Regional Francois Baclesse, Caen, 14076, France|Hopital Louis Pasteur, Colmar, 68024, France|Centre Hospitalier Universitaire Henri Mondor, Creteil, 94000, France|Centre Hospitalier Intercommunal des Alpes du Sud, Gap, 05007, France|Centre Oscar Lambret, Lille, 59020, France|Polyclinique des Quatre Pavillons, Lormont, 33310, France|Centre Leon Berard, Lyon, 69373, France|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, 13273, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, 34298, France|Clinique Hartmann, Neuilly sur Seine, 92200, France|Centre Antoine Lacassagne, Nice, 06088, France|Hopital Europeen Georges Pompidou, Paris, 75015, France|Hopital Saint-Louis, Paris, 75475, France|Hopital Saint Joseph, Paris, 75674, France|Hopital Tenon, Paris, 75970, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|CHU Poitiers, Poitiers, 86021, France|Institut Jean Godinot, Reims, 51056, France|Centre Eugene Marquis, Rennes, 35064, France|CHG Roanne, Roanne, F-42300, France|Clinique Armoricaine De Radiologie, Saint Brieuc, F-22015, France|Centre Rene Huguenin, Saint Cloud, 92211, France|Clinique Mutualiste, Saint Etienne, 42013, France|Institut de Cancerologie de la Loire, Saint Priest en Jarez, 42270, France|Institut Claudius Regaud, Toulouse, 31052, France|Centre Marie Curie, Valence, 26000, France|Centre Alexis Vautrin, Vandoeuvre-les-Nancy, 54511, France",
